NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive to Host Investor Morning on November 13, 2014

SAN DIEGO, CA -- (Marketwired) -- 11/03/14 -- NuVasive, Inc. (NASDAQ: NUVA) ("NuVasive" or the "Company"), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that it will host a meeting for investors and analysts on Thursday, November 13, 2014 from 8:00 a.m. to 10:00 a.m. PT at the W Hotel in San Francisco, California.

Several senior members of the executive team will provide an in-depth progress report on the top drivers of the Company's strategy for sustained growth with increasing profitability. Executive management in attendance will include:

  • Alex Lukianov, Chairman and Chief Executive Officer
  • Keith Valentine, Chief Operating Officer
  • Patrick Miles, President of Global Products and Services
  • Matt Link, Executive Vice President of U.S. Sales
  • Quentin Blackford, Executive Vice President and Chief Financial Officer
  • Russell Powers, Executive Vice President, International
  • Carol Cox, Executive Vice President, Strategy and Corporate Communications

A live webcast of the meeting and the presentation will be accessible online from the Investor Relations page of the Company's corporate website at

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the third largest player in the $8.7 billion global spine market. NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

NuVasive cautions you that statements included in this press release or made by management when participating in the above-described event that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of its network of sales representatives and the other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Investor/Media Contact:
Stacy Roughan
NuVasive, Inc.
Email Contact

Source: NuVasive, Inc.